Esketamine for Treatment-Resistant Depression - Johns Hopkins Medicine
There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours.
Esketamine for treatment‑resistant depression: A review of …
Esketamine nasal spray is recommended for adults diagnosed with major depressive disorder (MDD) who did not respond to at least two antidepressants, and who currently have a major …
FDA allows standalone use of nasal spray antidepressant Spravato ...
3 days ago · The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe …
FDA OKs Esketamine Nasal Spray Monotherapy for Depression
5 hours ago · The FDA first approved esketamine nasal spray for treatment-resistant depression in combination with an oral antidepressant, as reported by Medscape Medical News.
Esketamine: A New Approach for Patients with Treatment-Resistant Depression
Sep 26, 2019 · For patients with intractable depression, a new esketamine clinic — among the first in the U.S. — can provide immediate relief.
SPRAVATO® (esketamine) approved in the U.S. as the first and …
3 days ago · SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority Review, approval is …
Esketamine: A Drug to Treat Resistant Depression That Brings …
A novel and rapidly-acting antidepressant, esketamine, was approved by the Food and Drug Administration (FDA) in 2018 for “the treatment of depression in adults who have tried other …
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Oct 4, 2023 · In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect …
Esketamine: new hope for the treatment of treatment-resistant ...
The overall findings demonstrated that treatment with intranasal esketamine in combination with a new oral antidepressant was more effective than placebo plus an oral antidepressant, and …
Esketamine for Treatment-Resistant Depression — First FDA …
May 22, 2019 · The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset of effect against its …